ライフサイエンスコーパス: opioid peptide

1 s requires exocytosis of an endogenous kappa-opioid peptide.

2 neuropeptide that structurally resembles an opioid peptide.

3 ed from a precursor protein in the family of opioid peptides.

4 fects are many times greater than unmodified opioid peptides.

5 e for opiate alkaloids and is insensitive to opioid peptides.

6 the presence of raised levels of endogenous opioid peptides.

7 the state of active sleep, are modulated by opioid peptides.

8 the production and/or release of endogenous opioid peptides.

9 xhibit structural features suggestive of the opioid peptides.

10 h is involved in terminating the activity of opioid peptides.

11 as the stimulatory effects of the endogenous opioid peptides.

12 d changes in hippocampal pathways containing opioid peptides.

13 s, down to individual d-amino acids in small opioid peptides.

14 n the identification of the first endogenous opioid peptides.

15 sly been shown to improve bioavailability of opioid peptides.

16 t be the primary functions of the endogenous opioid peptides.

17 ffect may involve feeding-induced release of opioid peptides.

18 mus is an important brain area that produces opioid peptides.

19 hat exercise-induced increases in endogenous opioid peptides act in a manner similar to chronic admin

20 ick and Martinez to antagonism of endogenous opioid peptide action.

21 These results implicate endogenous opioid-peptide actions at mu opiate receptors in several

22 ese findings further suggest that endogenous opioid peptides activate mu opioid receptors to facilita

23 The intrinsic activities of all opioid peptide agonists and antagonists tested were not

24 h kelatorphan stabilizes putative endogenous opioid peptide agonists released by naloxone in GM1-trea

25 good assay for activation because endogenous opioid peptides all induce internalization.

26 Prodynorphin is processed into the opioid peptides, alpha-neoendorphin, and dynorphins A an

27 of possible autocrine and paracrine loops of opioid peptide and receptor expression have been identif

28 mu opioid receptors are targets of native opioid peptides and addictive analgesic drugs.

29 not show altered binding affinities for most opioid peptides and alkaloids tested.

30 Y (NPY) in the arcuate nucleus (ARC), and on opioid peptides and alpha-melanocyte stimulating hormone

31 are activated both by endogenously produced opioid peptides and by exogenously administered opiate c

32 Opioid peptides and glycyl-glutamine (Gly-Gln) have been

33 le for ECE2 in endocytic processing of delta opioid peptides and its effect on modulating delta opioi

34 eral inflamed tissue, both locally expressed opioid peptides and morphine can produce powerful analge

35 re the pharmacological targets of endogenous opioid peptides and morphine-like alkaloid drugs.

36 Effects of obesity on gene expression for opioid peptides and neuropeptide-Y (NPY) in the arcuate

37 IMG)-colon preparations to determine whether opioid peptides and neurotensin8-13 (NT8-13), the C-term

38 Opioid peptides and nociceptin/orphanin FQ (nociceptin)

39 accessible to released LE and possibly other opioid peptides and opiate drugs.

40 lular infiltration, and we examined synovial opioid peptides and opioid receptors by immunocytochemis

41 study was to examine the role of endogenous opioid peptides and opioid receptors specifically in the

42 nsfected cell models to a lesser degree than opioid peptides and other analgesic drugs, such as metha

43 id pharmacology and brain regional levels of opioid peptides and prodynorphin mRNA.

44 ucoprivation, lipoprivation and by different opioid peptides and receptor agonists.

45 The cloning of opioid peptides and receptors has led to the development

46 Expression of opioid peptides and receptors was measured using real-ti

47 l features and cellular actions with classic opioid peptides and receptors, but have distinct pharmac

48 trol regions of adult male songbirds contain opioid peptides and receptors, suggesting that opioids p

49 g 17beta-estradiol modulation of hippocampal opioid peptides and synaptic proteins while demonstratin

50 Opioid peptides and their receptors have been localized

51 suggest an important anticonvulsant role for opioid peptides and their receptors.

52 ch leads to an increased synaptic release of opioid peptides and to a naloxone-reversible hypoalgesic

53 by detecting c-Fos, an immediate early gene, opioid peptides and vesicular glutamate transporter 3 (V

54 ils of the delta opioid peptide (DOP), kappa opioid peptide, and mu opioid peptide receptors.

55 F), a tri-peptide contained in the dynorphin opioid peptide, and naloxone are neuroprotective at femt

56 ransmitters such as acetylcholine, dopamine, opioid peptides, and substance P in modulation of neurot

57 face, as measured by specific binding of the opioid peptide antagonist [(3)H]d-Phe((3)H)-Cys-Tyr-d-Tr

58 In the case of opioid peptides, antibodies are directed toward their C-

59 In contrast, the opioid peptides appear to influence the 'rewarding' aspe

60 growing body of evidence demonstrating that opioid peptides are an integral component of vertebrate

61 Opioid peptides are coreleased with catecholamines from

62 and evidence that members of this family of opioid peptides are endogenous agonists for the kappa op

63 Opioid peptides are involved in various essential physio

64 Endogenous opioid peptides are released at sites of injury, and the

65 sexual behavior, suggesting that endogenous opioid peptides are released during mating.

66 lating agent for the (68)Ga, and two related opioid peptides are used as targeting ligands for improv

67 s in animals implicate endogenous release of opioid peptides as a mechanism for terminating partial a

68 SOPT2 accepts endogenous and synthetic opioid peptides as substrates, but nonpeptide opiate ant

69 ates the physiological effects of endogenous opioid peptides as well as the structurally distinct opi

70 roduce NO in the presence of morphine or the opioid peptides at similar concentrations.

71 drolysates further confirmed the presence of opioid peptide BCM-7.

72 investigated along with extensively studied opioid peptide beta-casomorphin using a human intestinal

73 The opioid peptide beta-endorphin plays a critical role in b

74 lpha-melanocyte-stimulating hormone, and the opioid peptide beta-endorphin.

75 ntagonism by antisera against the endogenous opioid peptide beta-endorphin.

76 As the opioid peptides beta-endorphin and enkephalin increase s

77 Feeding induced by the mu-sensitive opioid peptide, beta-endorphin (betaEND, 10 microg, i.c.

78 Natural residues of the dimeric opioid peptide Biphalin were replaced by the correspondi

79 howed little or no response to a panel of 21 opioid peptides but still signaled normally in response

80 Immune cell-derived opioid peptides can activate opioid receptors on periphe

81 ide genes, including those encoding the anti-opioid peptide cholecystokinin, pronociceptive Substance

82 beta-Endorphin is an opioid peptide cleaved from the precursor pro-hormone pr

83 nhance detection of perikarya containing the opioid peptides, colchicine (90-100 microg/kg) was admin

84 Met-enkephalin is a small opioid peptide comprised of only five amino acids with m

85 e demonstrated that these novel, fluorescent opioid peptide conjugates permit real-time visual tracki

86 psin L for biosynthesis of active enkephalin opioid peptide contrasts with its function in lysosomes

87 Opioid peptides costored with glutamate have emerged as

88 This is the first opioid peptide cyclized through the N-terminus that reta

89 opexin domain or claudin-1 siRNA, enables an opioid peptide ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) a

90 Tolerance to the opioid peptide [d-Ala(2),N-MePhe(4),Gly-ol]-enkephalin w

91 te the effect of glycosylation on the cyclic opioid peptide [D-Cys(2,5),Ser(6),Gly(7)] enkephalin.

92 tal RPE cells by the uptake of the synthetic opioid peptide DADLE ((H-Tyr-D-Ala-Gly-Phe-D-Leu-OH) and

93 coumarinic acid (OMCA) cyclic prodrug of the opioid peptide DADLE ([D-Ala2,D-Leu5]-Enk, H-Tyr-D-Ala-G

94 sis we found that fentanyl and the synthetic opioid peptide DAMGO require M153 to induce beta-arresti

95 torphan, an inhibitor of multiple endogenous opioid peptide-degrading enzymes, stabilizes endogenous

96 withdrawal is enkephalin, a five-amino acid opioid peptide derived from the proenkephalin A family.

97 With the use of two fluorescent opioid peptides, dermorphin-Bodipy Texas Red and dermorp

98 Opioid peptides did not stimulate NO release, indicating

99 delta opioid peptide (DOP) receptors are considered a therapeu

100 linked to the C-terminal tails of the delta opioid peptide (DOP), kappa opioid peptide, and mu opioi

101 the efficacy of analogues of the endogenous opioid peptide dynorphin (Dyn) A have focused on the N-t

102 They are activated by the endogenous opioid peptide dynorphin (DYN) and expressed at particul

103 OR) is the primary target for the endogenous opioid peptide dynorphin (DYN), and KORs reside within b

104 omatic dynorphin) is a novel analogue of the opioid peptide dynorphin A with a nonbasic N-terminus th

105 A proline scan at positions 2 and 3 of the opioid peptide dynorphin A(1-11)-NH(2) led to the discov

106 The structural properties of the endogenous opioid peptide dynorphin A(1-17) (DynA), a potential ana

107 chronic stress are encoded by the endogenous opioid peptide dynorphin acting on specific stress-relat

108 nditions of host stress, levels of the human opioid peptide dynorphin are elevated, triggering virule

109 The kappa opioid peptide dynorphin is present in hilar mossy fiber

110 the shell of the nucleus accumbens where the opioid peptide dynorphin is upregulated in treated rats

111 The opioid peptide dynorphin seemed to be one target through

112 red Orphanin FQ, a peptide homologous to the opioid peptide Dynorphin, and its receptor, the Orphanin

113 ects of CREB activation on expression of the opioid peptide dynorphin, we microinjected the kappa-opi

114 ort the identification of a receptor for the opioid peptide dynorphin.

115 rojecting to the POA from PBN expressing the opioid peptides dynorphin and enkephalin.

116 he hypocretin peptide is colocalized with an opioid peptide, dynorphin.

117 ating evidence indicates that the endogenous opioid peptides dynorphinA-(1-17) and dynorphinA-(1-13)

118 previously described interactions of several opioid peptides [e.g., proopiomelanocortin, enkephalin (

119 other opiate drugs of abuse, and endogenous opioid peptides effect analgesia and alter mood.

120 n estradiol-containing hypothalamic loci and opioid peptides, elicits morphine-induced antinociceptio

121 y, the tryptophan-containing noncationizable opioid peptides emerged with atypical structure and unex

122 The endogenous opioid peptide endomorphin-1 (1) was modified by attachm

123 e the effects of morphine and the endogenous opioid peptides, endomorphin-1 (EM-1) and endomorphin-2

124 These findings indicate that the opioid peptide ENK and epinephrine may elicit concerted

125 The results, therefore, indicate that the opioid peptide, ENK, and the inhibitory amino acid, GABA

126 spinal glutamatergic synapses colocalize the opioid peptide enkephalin (ENK), but the neurons to whic

127 The endogenous opioid peptide, enkephalin, and epincphrine are distribu

128 d a long-term elevation of the proconvulsive opioid peptide, enkephalin, in the rat hippocampus.

129 MOR are localized in neurons containing the opioid peptide, enkephalin, within the dorsolateral stri

130 Endogenous opioid peptides (EOPs) have been shown to play an import

131 Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).

132 characterized, the direct quantification of opioid peptide exocytosis events has not previously been

133 ich include potentially important changes in opioid peptide expression and/or activity.

134 In contrast, opioid peptides failed to induce NO release, consistent

135 Dynorphin opioid peptides, for their part, bind to the acidic pock

136 tral activation of MRGPRX1 by the endogenous opioid peptide fragment BAM8-22 and its positive alloste

137 oenkephalin and that the generation of small opioid peptides from intermediates is mediated almost en

138 L-4 receptor a (IL-4Ra)-dependent release of opioid peptides from M1 macrophages at injured nerves.

139 injured nerves attenuates pain by releasing opioid peptides from the infiltrating macrophages in mic

140 an allostatic state (decreased dopamine and opioid peptide function, increased corticotropin-releasi

141 These results show that native opioid peptides function in wound healing, and exert a t

142 uences of the cannabinoid receptor system on opioid peptide gene expression and on dopamine receptor

143 , as has been noted in energy-deprived rats, opioid peptide gene expression is decreased in the ARC o

144 ulatory effect on D(4) dopamine receptor and opioid peptide gene expression.

145 Opioid peptide genes, compared with their receptor genes

146 rters, we synthesized cyclic prodrugs of the opioid peptides H-Tyr-Ala-Gly-Phe-D-Leu-OH ([Ala2,D-Leu5

147 These data indicate that opioid peptides have a modulatory effect on NRGc-evoked

148 ding, although roles for specific endogenous opioid peptides have barely been addressed.

149 A series of opioid peptides have been developed in which the change

150 Endogenous opioid peptides have been linked to numerous physiologic

151 efly review the history of identification of opioid peptides, highlight the major findings, address s

152 uld increase neurotransmission of endogenous opioid peptides (i.e., endorphins) in the nucleus accumb

153 O following treatment with morphine, but not opioid peptides (i.e., Met-enkephalin).

154 early 1970s and the discovery of endogenous opioid peptides in 1975.

155 ide a route for more efficient production of opioid peptides in applications for chronic pain treatme

156 To test the hypothesis that opioid peptides in LC afferents are altered after chroni

157 ctrometry (LC-MS(3)) to determine endogenous opioid peptides in microdialysis samples collected in vi

158 expected on the basis of previous studies of opioid peptides in other avian species, including pigeon

159 Changes in the expression of these opioid peptides in presumed dopamine target neurons, whi

160 ve been used to explore the functions of the opioid peptides in specific behaviors and brain circuits

161 Endogenous opioid peptides in the amygdala regulate many of our beh

162 t significantly influence gene expression of opioid peptides in the ARC in either the lactating or th

163 cation stage involve changes in dopamine and opioid peptides in the basal ganglia.

164 NO)-dependent neuronal release of endogenous opioid peptides in the central nervous system.

165 By consequence, the inhibitory actions of opioid peptides in the dorsal vagal complex may depend o

166 In this opinion article, novel actions of mu-opioid peptides in the prefrontal cortex (PFC) that coul

167 characterize neuronal pathways that release opioid peptides in the rat dorsal horn, multiple-label i

168 mitter receptors that inhibit the release of opioid peptides in the spinal cord may play an important

169 ve-salience and/or reward systems (dopamine, opioid peptides) in the ventral striatum and from the be

170 Expression of dynorphin, an endogenous opioid peptide, increases with age and has been associat

171 by naturally occurring endomorphin-1 and -2 opioid peptides, indicating a role of opioid involvement

172 Although opioid peptides induce internalization in vivo, there ar

173 ce of L-NAME (10(-4) M), indicating that the opioid peptide inhibition of the presynaptic release of

174 A decrease in endogenous opioid peptide inhibitory tone on the afternoon of proes

175 this receptor (opiate alkaloid selective and opioid peptide insensitive).

176 activation of the opiate alkaloid-selective, opioid peptide-insensitive micro3 receptor, and that fun

177 supports the opiate alkaloid selectivity and opioid peptide insensitivity of this receptor.

178 the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in t

179 gs support a significant role for endogenous opioid-peptide interactions with mu opiate receptors in

180 ture, we sought to identify and describe the opioid peptides intrinsic to the RAIC by using immunohis

181 ber of synthetic compounds but does not bind opioid peptides; it is currently considered an orphan re

182 abeled for methionine-enkephalin (M-ENK), an opioid peptide known to be an endogenous ligand of the d

183 ts of dynorphin A can be reversed by a kappa-opioid peptide (KOP) receptor antagonist nor-binaltorphi

184 these were immunolabeled for the endogenous opioid peptide L-ENK.

185 ass spectrometry of sEVs detected endogenous opioid peptide leu-enkephalin.

186 ost-synaptic proteins, including PSD-95, and opioid peptides leu-enkephalin and dynorphin in the hipp

187 ationship between the MOR and the endogenous opioid peptide, Leu5-enkephalin (LE).

188 ctions that were also dually labeled for the opioid peptide leucine-enkephalin (L-ENK).

189 d the immunocytochemical localization of the opioid peptide leucine5-enkephalin (ENK) and the epineph

190 Such alterations in opioid peptide levels during opiate dependence may contr

191 of ovarian hormones on synaptic protein and opioid peptide levels in the aging hippocampus is unders

192 elective, conformationally constrained delta-opioid peptide ligand [(2S, 3R)-TMT1]DPDPE, a series of

193 following systemic administration of the new opioid peptide may be explained by activation of vagal a

194 We therefore suggest that endogenous opioid peptides may act as neuromodulators to regulate i

195 a demonstrate several sites where endogenous opioid peptides may interact with mu OR receptive sites

196 ide Y may initiate feeding for energy needs, opioid peptides may provide the rewarding aspects of eat

197 ith IL-4 dose dependently secreted all three opioid peptides measured by immunoassays.

198 one, its neuroactive steroid metabolite, and opioid peptide mechanisms.

199 dynorphin demonstrates that this endogenous opioid peptide mediates the dysphoric effects of marijua

200 undertaken to investigate the effects of the opioid peptide Met-enkephalin (met-enk) on the release o

201 lin, 75 and 96% yields were obtained for the opioid peptides Met-RGL and Met-enk, respectively.

202 Opioid growth factor (OGF) is an endogenous opioid peptide ([Met(5)]enkephalin) that interacts with

203 An endogenous opioid peptide, [Met5]-enkephalin, termed opioid growth

204 A native opioid peptide, [Met5]-enkephalin, termed opioid growth

205 A native opioid peptide, [Met5]-enkephalin, termed opioid growth

206 In addition to neurotransmission, the native opioid peptide, [Met5]enkephalin, is a tonically active

207 The opioid peptide metenkephalin is a natural substrate of N

208 fe, was examined for immunoreactivity to the opioid peptide methionine enkephalin (mENK).

209 ester and unresponsive to stimulation by the opioid peptide methionine enkephalin.

210 ous axon terminals containing the endogenous opioid peptide, methionine5-enkephalin (ENK), that forme

211 temic administration of a novel glycosylated opioid peptide MMP-2200 (a.k.a. lactomorphin) was shown

212 The opioid peptide MMP-2200 blocked the apomorphine-induced

213 dence are mediated by its activity at the mu opioid peptide (MOP) receptor [1].

214 We characterized the effects of the mu opioid peptide (MOP) receptor agonist buprenorphine and

215 tch scratching, which can be inhibited by mu-opioid peptide (MOP) receptor and GRP receptor (BB2) ant

216 opamine neurons also express postsynaptic mu-opioid peptide (MOP) receptors.

217 to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP

218 there is a decrease in the synthesis of the opioid peptide mRNA and protein in the medullo-coerulear

219 dition: food-seeking roaming mediated by the opioid peptide NLP-24 and dauer formation mediated by ph

220 Activation of the nociceptin opioid peptide (NOP) receptor by its endogenous ligand N

221 denced by the abrogation of N/OFQ-nociceptin opioid peptide (NOP) receptor signalling and inhibition

222 Agonists of the nociceptin/orphanin FQ opioid peptide (NOP) receptor, a member of the opioid re

223 n to decrease N/OFQ and increase nociceptive opioid peptide (NOP) receptors in the nucleus accumbens.

224 moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have utility as a re

225 These results indicate that an endogenous opioid peptide, OGF, and its receptor are present and go

226 These results show that an opioid peptide, OGF, plays a direct role in the repair o

227 investigate the possible role of a specific opioid peptide on EtOH consumption.

228 imply that the central inhibitory action of opioid peptides on gastrointestinal function targets sel

229 es were designed to determine the actions of opioid peptides on synaptic transmission within the dors

230 vation in rats on the expression of striatal opioid peptide (OP) genes that subserve food motivation

231 y, we investigated the effects of one native opioid peptide, opioid growth factor ([Met(5)]-enkephali

232 The opioid peptide, Orphanin FQ/nociceptin (OFQ/N(1-17))(,)

233 phin and enkephalin knock-out mice that both opioid peptides play a positive role.

234 Instead, the opioid peptides play complex and overlapping roles in a

235 The opioid peptides PPD and PPE were expressed in the fetal

236 s been engineered to contain the cDNA for an opioid peptide precursor, human preproenkephalin, under

237 to food restriction since regional levels of opioid peptides, precursor mRNA, and receptor binding ha

238 us peptide activity, and genetic knockout of opioid peptide precursors.

239 Opioid peptides produce gastrointestinal inhibition and

240 r concentrations of ketamine with endogenous opioid peptides produced robust synergistic responses wi

241 dy PC2-dependent proteolytic events, such as opioid peptide production.

242 (Penk), encoding the precursor of analgesic opioid peptides, ranks among the top 25 genes most enric

243 Previous studies showed that the delta-opioid peptide receptor (DOP-R) is dynamically regulated

244 Agonists at the nociceptin opioid peptide receptor (NOP) are under investigation as

245 Nociceptin, which binds to the nociceptin opioid peptide receptor (NOP), regulates stress and rewa

246 elta (DOP), kappa (KOP) and nociceptin (NOP) opioid peptide receptor genes have been able to differen

247 ivo was explored by examining the effects of opioid peptide-receptor disruption using topical applica

248 e sarcolemma contains both catecholamine and opioid peptide receptors (OPRs).

249 Here, we show that opioid peptide receptors, GPCRs that mediate highly sens

250 peptide (DOP), kappa opioid peptide, and mu opioid peptide receptors.

251 e 1 (HIV-1), and recent studies suggest that opioid peptides regulate the function of macrophages fro

252 low, can be partially relieved by endogenous opioid peptide release.

253 A1 neurons, uncovering regionally restricted opioid peptide release.

254 Rs) provides an ideal way to locate areas of opioid peptide release.

255 Protecting enkephalins, endogenous opioid peptides released in response to nociceptive stim

256 or (MOP) is activated by numerous endogenous opioid peptides, remains an attractive therapeutic targe

257 peptides are among the most kappa-selective opioid peptides reported to date, showing comparable or

258 The opioid peptides represent a major class of neurotransmit

259 response to dietary factors; release of the opioid peptides requires the Trpm5 ion channel.

260 c experiments demonstrated that intermediate opioid peptides secreted from SCH activate CXCR7, a beta

261 ver, the specific brain regions within which opioid peptide secretion contributes to the maintenance

262 Endogenous opioid peptides serve as growth factors in developing, r

263 Endogenous opioid peptides serve as growth factors in developing, r

264 Thus, the opioid peptides show either relatively low affinity or n

265 re that NOPLight can be used to detect N/OFQ opioid peptide signal dynamics in tissue and freely beha

266 New approaches for studying endogenous opioid peptide signaling and release and the dynamics of

267 o-injected antibody to IL-4Ra, antibodies to opioid peptides such as Met-enkephalin (ENK), B-endorphi

268 to mu OR-labeled dendrites may contain other opioid peptides, such as methionine-enkephalin.

269 e potential presence of other members in the opioid peptide superfamily.

270 ugh P2 receptor-mediated mechanism, and that opioid peptides suppress these afferents' activity.

271 re, these data support an active role of the opioid peptide system in the inhibition of the reproduct

272 hasize complex interplays between endogenous opioid peptides targeting mu-receptors, such as enkephal

273 tors, can cause the release of an endogenous opioid peptide that binds to mu opioid receptors within

274 illamine(2,5)-enkephalin (DPDPE) is a potent opioid peptide that exhibits a high selectivity for the

275 f the anionic residue Asp4 by Aib yielded an opioid peptide that fit two-site binding models for the

276 immunoperoxidase labeling of dynorphin A, an opioid peptide that is abundant in normal mossy fibers.

277 Beta-endorphin is an endogenous opioid peptide that is released during stress and has be

278 Dynorphin A is an endogenous opioid peptide that produces non-opioid receptor-mediate

279 Its major components include a panel of opioid peptides that activate four canonical inhibitory

280 d release of endogenous prodynorphin-derived opioid peptides that activated an anti-nociceptive KOR s

281 Enkephalins are endogenous opioid peptides that are derived from a pre-proenkephali

282 In sharp contrast to all-natural product opioid peptides that efficaciously recruit beta-arrestin

283 cine-enkephalin (L-ENK) are small endogenous opioid peptides that have been implicated in a wide vari

284 rphins represent a novel group of endogenous opioid peptides that have high affinity for the mu-opioi

285 t estrogen induces the release of endogenous opioid peptides that in turn activate the MOR.

286 Enkephalins are opioid peptides that modulate analgesia, reward, and str

287 The inability of opioid peptides to be transported through epithelial mem

288 bservations that demonstrated the failure of opioid peptides to promote cell rounding.

289 stinal repair, and sodium chloride-dependent opioid peptide transport.

290 es of human DPP III and its complex with the opioid peptide tynorphin, which rationalize the enzyme's

291 immunoassay for Leu-enkephalin, a mammalian opioid peptide, using a C-terminal aequorin-peptide fusi

292 e capability of a representative type of non-opioid peptides vasoactive intestinal peptide (VIP) in t

293 pathways, both of which contain and release opioid peptides, we tested the hypothesis that inactivat

294 overcome this obstacle, six new fluorescent opioid peptides were developed.

295 cocaine is causing the release of endogenous opioid peptides which activate mu opioid receptors withi

296 stable surrogate for enkephalins, endogenous opioid peptides, which exert cardiodepressive effects an

297 Dynorphin(1-8), an opioid peptide with high selectivity for the kappa-opioi

298 y injury increased the release in the RVM of opioid peptides with preferential affinity for the delta

299 s by comparing absolute expression levels of opioid peptides with their receptors, the largest neurop

300 Endogenous opioid peptides within the nucleus accumbens, a forebrai